Process vs. Material Origins
Nitrosamine impurities originate from active pharmaceutical ingredient (API) synthetic pathways, degraded raw materials, or chemical interactions involving excipients. In contrast, nitrosamine leachables arise from external packaging components, including elastomeric stoppers, blister films, printed overwraps, and other packaging materials that gradually migrate into the drug formulation throughout its shelf life.
To deepen your understanding of these specific origins, learn more about Nitrosamine formation pathways in API synthesis.
Distinct Regulatory Frameworks
Nitrosamine impurities are controlled under the “cohort of concern” principles established in ICH M7 and USP guidelines. Nitrosamine leachables, however, are managed through established extractables and leachables (E&L) programs utilizing USP, USP, ISO 10993-18, and the forthcoming ICH Q3E guideline. Determining whether a specific drug requires an extensive evaluation is a critical first step; you can explore more here: Do all drugs need nitrosamine risk assessment?.
The Carcinogenic Potency Categorization Approach (CPCA)
While synthesis-related nitrosamine impurities are rigorously assessed based on their chemical structures and metabolic activation potential to establish limits ranging from 18 to 1500 ng/day, packaging-derived nitrosamine leachables associated with critical acute therapies may be evaluated using adjusted exposure factors that can be 4- to 10-fold higher under specific regulatory circumstances. For further guidance on regulatory requirements, visit Genotoxic impurity testing ICH M7 and Nitrosamines.
Advanced Trace Analysis
The detection of both mutagenic categories requires highly sensitive analytical techniques, including Gas Chromatography-Mass Spectrometry (GC-MS/MS) and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS), capable of measuring concentrations at parts-per-billion (ppb) and even parts-per-trillion (ppt) levels.
If you are looking for expert method development, see Nitrosamine method development and validation services.
Article Summary:
- Nitrosamine contamination in pharmaceuticals can originate from two primary sources: manufacturing processes (impurities formed during API synthesis, solvent use, or degradation) and packaging materials that release nitrosamine-related compounds into drug products over time.
- Process-related nitrosamines are typically generated when amines react with nitrosating agents under favorable conditions such as acidity, heat, or moisture. These contaminants may appear as either small-molecule nitrosamines or API-specific nitrosamine drug substance-related impurities (NDSRIs).
- Packaging-derived nitrosamine leachables can migrate from elastomeric stoppers, rubber closures, blister films, inks, adhesives, and overwrap materials. Environmental factors such as humidity, elevated temperatures, irradiation, and long-term storage can increase migration rates.
- Regulatory authorities apply different frameworks to evaluate these risks. Process-related impurities are generally assessed under ICH M7 and related FDA/EMA guidance, while packaging-derived nitrosamines are addressed through extractables and leachables (E&L) programs supported by USP, ISO standards, and emerging ICH Q3E requirements.
- Extractables studies identify chemicals that could potentially be released from packaging materials under aggressive laboratory conditions, whereas leachables studies determine whether those compounds actually migrate into drug products during normal storage and use.
- Risk assessments for process impurities focus on chemical synthesis pathways, contamination sources, and formation likelihood, while leachable assessments evaluate migration mechanisms, packaging materials, environmental stresses, and long-term product stability.
- Detecting nitrosamines requires highly sensitive analytical techniques such as LC-MS/MS, LC-HRMS, and GC-MS/MS capable of measuring trace concentrations at parts-per-billion or parts-per-trillion levels. Robust testing, validated methods, and targeted mitigation strategies are essential for maintaining regulatory compliance, preventing product recalls, and ensuring patient safety.
Comprehensive Analysis of the Nitrosamine Impurity vs Nitrosamine Leachable Difference
Distinguishing between process-derived impurities and packaging-derived leachables is essential for developing scientifically robust safety assessments and achieving regulatory approval. To maintain regulatory compliance and ensure patient safety, pharmaceutical manufacturers must clearly understand the Nitrosamine Impurity vs Nitrosamine Leachable Difference with respect to origin, chemical behavior, formation mechanisms, and toxicological evaluation. For a foundational overview, read What are Nitrosamines?.
Historically, the discovery of trace nitrosamines in widely prescribed medications such as valsartan, ranitidine, and metformin resulted in significant product recalls and exposed the susceptibility of pharmaceutical manufacturing processes to mutagenic side reactions. As investigations progressed, it became evident that nitrosamines were not exclusively associated with synthetic pathways. Packaging materials, including elastomeric closures, blister packaging systems, and multi-layer infusion bags, were also identified as potential sources of contamination. These materials can act as hidden vectors of risk by introducing pre-formed nitrosamines or nitrosamine precursors that migrate directly into therapeutic formulations over time.
This technical monograph examines the physicochemical pathways, regulatory expectations, and advanced analytical methodologies required to identify, evaluate, and control both categories of mutagenic compounds.
Mechanisms and Formation of Process-Related Nitrosamine Impurities
Process-related nitrosamine impurities are formed through reactions between secondary, tertiary, or quaternary amines and nitrosating agents within acidic reaction environments. Under acidic conditions, nitrites are converted into highly reactive nitrous acid, which subsequently decomposes into reactive nitrogen species such as nitrous anhydride. These intermediates rapidly react with available amine groups, resulting in the formation of stable N-nitrosamines.
Learn more about assessing risk for your specific drug products at Do all drugs need nitrosamine risk assessment?.
The structural landscape of nitrosamine impurities can be categorized into two distinct groups:
Small-Molecule Nitrosamine Impurities
These low-molecular-weight volatile or semi-volatile compounds, including NDMA, N-nitrosodiethylamine, and N-nitrosodibutylamine, do not share structural similarity with the active pharmaceutical ingredient. They may occur across a broad range of drug products and manufacturing processes.
Nitrosamine Drug Substance-Related Impurities (NDSRIs)
These more complex, non-volatile compounds share structural similarity with the API itself. NDSRIs are generally unique to a specific active ingredient and are formed when secondary or tertiary amine groups within the API structure or its degradation fragments undergo nitrosation.
Amine Precursor (API / Solvent / Reagent) + Nitrosating Agent (Nitrite / Nitrous Acid)
│
▼ (Acidic / Heated / Humid Environment)
Stable Mutagenic N-NitrosamineProcess-related impurities can be introduced through several critical pathways during drug substance and drug product manufacturing:
Synthetic Route Intermediates
The use of sodium nitrite in the presence of secondary or tertiary amines, which are often present as solvent impurities such as dimethylformamide (DMF), represents a well-established pathway responsible for the historical valsartan recalls.
Recycled and Contaminated Solvents
Recycled solvents such as triethylamine and diisopropylamine, as well as catalysts contaminated with trace amines, may carry residual nitrosating agents. These contaminants can initiate secondary nitrosamine formation during subsequent manufacturing campaigns.
Formulation Degradation
Certain APIs exhibit inherent instability and may undergo intramolecular rearrangements or degradation under normal storage conditions. Ranitidine serves as a notable example, as its molecular structure contains both amine and nitro functional groups. This composition makes the molecule vulnerable to self-degradation and thermal decomposition, resulting in NDMA formation over the product’s shelf life.
Because these compounds belong to the highly carcinogenic “Cohort of Concern” defined by ICH M7, even trace-level concentrations present a substantial public health concern and must be controlled through careful process design and risk mitigation strategies.
Migration Pathways of Packaging-Derived Nitrosamine Leachables
Nitrosamine leachables enter pharmaceutical products when chemical precursors or pre-formed mutagenic compounds migrate from container closure systems into the formulation during storage. This migration process occurs either through direct contact with liquid formulations or through gaseous diffusion across polymeric and elastomeric barriers. For details on how leachables are identified, see Packaging leachables and nitrosamine extractables/leachables.
The generation and release of nitrosamine leachables commonly involve interactions associated with polymers, elastomers, and secondary packaging components.
Elastomeric Closures and Rubber Stoppers
Elastomeric materials are frequently vulcanized using accelerators such as thiurams and dithiocarbamates. During manufacturing and compounding, these substances can degrade and release secondary amines, including dibutylamine. When exposed to trace nitrites, moisture, and elevated temperatures, these amines undergo nitrosation and generate volatile nitrosamines such as NDBA.
Blister Films (PVC and PVdC)
Polyvinyl chloride (PVC) and polyvinylidene chloride (PVdC) films may contain residual nitrites originating from polymer stabilization processes or manufacturing operations. Under humid conditions, these nitrites can migrate toward the surface and react with secondary or tertiary amines present in plasticizers, adhesive systems, lacquer coatings, or even the pharmaceutical formulation itself, thereby promoting localized nitrosamine formation.
Secondary Packaging, Inks, and Overwraps
As highlighted in the FDA safety alert issued on August 18, 2025, printed overwraps and flexible pouches used with infusion bags can represent significant sources of leachable nitrosamines. Many packaging inks contain dialkylamines, while others utilize nitrocellulose-based binders. Exposure to thermal stress and mechanical compression during overwrap sealing can facilitate reactions that generate small-molecule nitrosamines, particularly NDBA. These compounds may subsequently migrate through the polymer membrane of the primary container and enter the drug solution.
Historical occupational monitoring data from rubber manufacturing facilities have long demonstrated a relationship between vulcanization accelerators and carcinogenic exposure risks. When applied to pharmaceutical packaging safety, these findings underscore the importance of stringent controls on rubber formulations and migration behavior.
For example, European Directive 93/11/EEC limits the total release of nitrosamines from rubber teats and soothers to 0.01 mg/kg. Within pharmaceutical container closure systems, compounding standards such as USP require comprehensive oversight to prevent the migration of volatile nitrosamines, including N-nitrosomorpholine (NMOR) and NDBA, into parenteral products and inhalation therapies.
The Critical Role of Extractables and Leachables Characterization
Extractables are chemical compounds that can be forcibly removed from materials under aggressive laboratory conditions, whereas leachables represent the subset of those compounds that actually migrate into a drug product during routine storage and clinical use.
This distinction is critically important. Extractables studies are designed to evaluate worst-case scenarios and identify all potential chemical risks associated with a material. Leachables studies, on the other hand, determine the actual patient exposure to those compounds under real-world conditions.
┌─────────────────────────────────────────────────────────┐
│ EXTRACTABLES PROFILE │
│ Identified under aggressive lab solvents and heat │
│ ┌─────────────────────────────────────────────────┐ │
│ │ LEACHABLES PROFILE │ │
│ │ Migrates under shelf-life storage conditions │ │
│ │ ┌─────────────────────────────────────────┐ │ │
│ │ │ NITROSAMINE LEACHABLES │ │ │
│ │ │ Mutagenic subset of concern │ │ │
│ │ └─────────────────────────────────────────┘ │ │
│ └─────────────────────────────────────────────────┘ │
└─────────────────────────────────────────────────────────┘Analytical evaluation requires exposing materials such as elastomeric stoppers, plastic tubing, and single-use process bags to aggressive solvents, elevated temperatures, and accelerated sterilization conditions. When secondary amines or pre-formed nitrosamines are detected in these extracts, manufacturers must perform downstream leachables studies to determine whether these substances migrate into the actual pharmaceutical product over time.
Key Differences in Risk Assessments and Chemistry Protocols
Evaluating the Nitrosamine Impurity vs Nitrosamine Leachable Difference requires distinct analytical strategies. Process-related impurities are assessed through synthesis-based risk evaluations, while packaging-related leachables are investigated through comprehensive extractables and leachables studies.
Although both approaches are rooted in scientific risk assessment principles, their analytical objectives, testing methodologies, and experimental parameters differ substantially.
Process impurity assessments focus on determining the thermodynamic and kinetic probability of nitrosamine formation during chemical synthesis. This includes evaluating synthetic pathways, reviewing incoming solvent quality, calculating theoretical purge factors, and assessing contamination risks associated with shared manufacturing equipment.
In contrast, leachable risk assessments focus on physical migration mechanisms, diffusion kinetics through semi-permeable polymeric materials, and environmental stress factors. The scope of these evaluations extends across primary packaging components, secondary packaging materials, closure systems, and manufacturing equipment such as tubing, mixers, and single-use bioreactors.
| Technical Parameter | Nitrosamine Impurities Assessment | Nitrosamine Leachables Assessment |
|---|---|---|
| Primary Physical Source | API synthetic pathways, process solvents, catalysts, raw material reagents, or formulation degradation | Primary container closure systems, secondary packaging, inks, labels, and adhesives |
| Analytical Target Scope | Process-specific small-molecule nitrosamines and API-specific NDSRIs | Packaging-specific nitrosamines such as NDBA, NMOR, NPYR, and NPIP |
| Inherent Matrix Interference | Typically evaluated within a defined API or excipient matrix | Frequently involves complex formulations, parenteral emulsions, and infusion products |
| Stressed Study Parameters | Synthesis conditions, pH variation, process heat, and purge kinetics | Accelerated aging studies, gamma irradiation, and multi-solvent extraction programs |
| Primary Regulatory Guidelines | ICH M7, USP, FDA, EMA | USP, USP, ISO 10993-18, and emerging ICH Q3E |
| Control Strategy Focus | Process optimization, purge calculations, and raw material control | Material selection, low-amine elastomers, barrier technologies, and packaging optimization |
Environmental conditions significantly influence the migration of packaging-derived leachables. A product that meets specifications immediately after manufacturing may experience increased migration during prolonged exposure to heat, humidity, ultraviolet radiation, or sterilization procedures such as gamma irradiation and autoclaving. These factors can accelerate precursor migration and activate latent nitrosation pathways within packaging materials.
Regulatory Landscapes and Acceptable Intake Limits
Regulatory authorities distinguish process-related mutagenic impurities from packaging-derived leachables by applying separate toxicological frameworks and compliance requirements. The evaluation of mutagenic compounds is based on establishing acceptable daily exposure levels throughout a patient’s lifetime.
For process-related nitrosamine impurities, the Carcinogenic Potency Categorization Approach (CPCA) serves as the primary framework employed by both the FDA and EMA when direct carcinogenicity data are unavailable. The CPCA evaluates structural characteristics, including steric and electronic properties surrounding the N-nitroso group, and assigns compounds to one of five potency categories.
Category 1
Highly potent compounds with a recommended Acceptable Intake (AI) limit of 18 ng/day.
Category 2
Compounds assigned AI limits ranging from 26.5 ng/day to 100 ng/day, depending on available toxicological evidence.
Category 3
Compounds assigned AI limits ranging from 150 ng/day to 400 ng/day.
Category 4
Compounds assigned an AI limit of 1500 ng/day.
Category 5
Low-potency compounds with an AI limit of 1500 ng/day.
| CPCA Potency Category | Structural Criteria Summary | Recommended AI Limit |
| Category 1 | Highly unhindered, electronically activated structures with strong metabolic activation potential | 18 ng/day |
| Category 2 | Moderate steric hindrance around the N-nitroso center | 26.5 ng/day to 100 ng/day |
| Category 3 | Significant steric hindrance or deactivating substituents | 150 ng/day to 400 ng/day |
| Category 4 | Highly hindered or strongly deactivated structures | 1500 ng/day |
| Category 5 | Negligible carcinogenic potency based on structural assessment | 1500 ng/day |
Traditional extractables and leachables programs typically rely on the Safety Concern Threshold (SCT), which is generally established at 1.5 μg/day, to determine the Analytical Evaluation Threshold (AET) for unidentified compounds. However, nitrosamines belong to the “Cohort of Concern” and therefore are not subject to conventional SCT-based limits. Instead, they must be controlled using compound-specific toxicological thresholds that are substantially lower.
For packaging-derived leachables, regulators recognize that complete elimination may not always be feasible without jeopardizing the availability of essential medicines. Consequently, several regulatory mechanisms have been implemented.
Adjusted AI Limits for Infusions
Following the identification of NDBA in infusion products, the FDA’s Center for Drug Evaluation and Research (CDER) permitted adjustment factors ranging from 4- to 10-fold above lifetime AI limits for certain critical therapies. This approach reflects the unique exposure circumstances associated with emergency medicine, parenteral nutrition, and other acute-care applications.
Less Than Lifetime (LTL) Exposure
Under ICH M7 and EMA guidance, manufacturers may apply Less Than Lifetime (LTL) exposure principles during short-term treatment periods. For therapies lasting less than one month, daily intake limits may be increased to as much as 120 μg/day, helping prevent drug shortages while corrective and preventive actions (CAPA) are implemented.
Transition to ICH Q3E
The advancement of ICH Q3E to Step 2b marks a major regulatory milestone. The guideline promotes a globally harmonized, lifecycle-based framework for extractables and leachables management, ensuring that packaging-derived contaminants receive a level of scientific scrutiny comparable to that applied to active pharmaceutical ingredient impurities.
Together, these regulatory approaches ensure that both synthesis-related and packaging-derived mutagenic compounds remain controlled at levels that pose negligible risk to patients.
Advanced Chromatographic and Mass Spectrometric Testing Methodologies
Detecting nitrosamines at trace concentrations requires highly sensitive chromatographic separation coupled with advanced mass spectrometric detection. Conventional UV-Vis and flame ionization detectors do not provide the sensitivity or selectivity necessary to identify and quantify trace mutagenic contaminants within complex pharmaceutical matrices or polymer-derived extracts.
USP General Chapter outlines four highly sensitive analytical procedures that support both risk assessment activities and routine quality control testing.
| USP Procedure | Analytical Platform | Target Nitrosamines | Matrix Applicability |
| Procedure 1 | Liquid Chromatography-High-Resolution Mass Spectrometry (LC-HRMS) | NDMA, NDEA, NDBA, NDIPA, NEIPA, NMBA, NMPA | Broad applicability across APIs and formulations with high-resolution mass accuracy |
| Procedure 2 | Headspace Gas Chromatography-Tandem Mass Spectrometry (HS-GC-MS/MS) | NDMA, NDEA, NDIPA, NEIPA | Optimized for highly volatile nitrosamines |
| Procedure 3 | Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) | NDMA, NDEA, NDIPA, NEIPA, NMBA, NDBA | Commonly applied to sartan products such as valsartan, losartan, olmesartan, candesartan, and telmisartan |
| Procedure 4 | Direct Injection Gas Chromatography-Tandem Mass Spectrometry (GC-MS/MS) | Volatile nitrosamine targets | High-sensitivity analysis using multiple reaction monitoring (MRM) |
Successful implementation of these procedures requires overcoming several complex analytical challenges.
Column Chemistry and Stationary Phase Selection
Chromatographic methods must provide adequate separation between the dominant API signal and trace-level nitrosamine analytes. In Procedure 3, this objective is achieved through the use of a 150 × 3.0 mm Ascentis Express C18 column (USP L1 packing) containing 2.7 μm particles, which provide excellent peak shape and resolution. In Procedure 1, pentafluorophenyl (PFP) bonded phases such as L43 columns are frequently employed because their unique retention mechanisms improve separation of closely eluting polar compounds.
Matrix Suppression and Divert Valve Strategies
Co-eluting matrix components can suppress ionization within the mass spectrometer source and lead to artificially low nitrosamine results. To mitigate this effect, modern analytical methods employ switching valves that divert large API peaks to waste while directing well-resolved nitrosamine analytes into the mass spectrometer.
Trace Reference Standard Traceability
Accurate quantification at ppb and ppt levels requires high-purity, traceable reference standards. Without certified reference materials, laboratories face increased risks of false-positive findings, inaccurate quantitation, method validation failures, regulatory observations, and costly product recalls.
To satisfy global regulatory expectations, all analytical methods must be validated according to ICH Q2(R2) and applicable regional requirements.
| Validation Parameter | ICH Q2(R2) Acceptance Criteria | Nitrosamine-Specific Analytical Consideration |
| Limit of Quantitation (LOQ) | S/N ≥ 10:1, Precision ≤ 20% RSD | Must be significantly below the toxicological action limit |
| Linearity | Correlation coefficient R² ≥ 0.99 | Should cover 0.5× to 2.0× the target specification limit |
| Accuracy / Recovery | 80% to 120% recovery | Requires deuterated internal standards such as NDMA-d₆ and NDBA-d₁₈ |
| Specificity | No interference at analyte retention time | Confirmed using degraded matrices and blank injections |
| Robustness | Recovery variation ≤ 10% | Must demonstrate stability across minor method changes |
Through the application of these advanced chromatographic and mass spectrometric methodologies, pharmaceutical manufacturers can confidently identify, quantify, and control both process-related nitrosamine impurities and packaging-derived nitrosamine leachables.
Strategic Conclusions on the Nitrosamine Impurity vs Nitrosamine Leachable Difference
A comprehensive pharmaceutical quality strategy must clearly distinguish between process-related impurities and packaging-derived leachables in order to prevent recalls, maintain regulatory compliance, and protect patient safety. Understanding the Nitrosamine Impurity vs Nitrosamine Leachable Difference allows quality and regulatory teams to implement targeted mitigation strategies. Process-related impurities are controlled through synthesis optimization, solvent purification, raw material qualification, and API structural risk assessments. Packaging-derived leachables, by contrast, are managed through the selection of low-amine elastomers, optimization of blister packaging systems, implementation of high-barrier materials, and rigorous extractables and leachables evaluations.
By partnering with experienced analytical testing laboratories, pharmaceutical manufacturers can conduct highly sensitive USP-compliant mass spectrometry testing and comprehensive extractables and leachables studies that support regulatory submissions, facilitate product approvals, and safeguard patient health. Start your path toward compliance by exploring expert outsourcing options at Outsourcing nitrosamine testing to a CRO.
For custom extractables and leachables studies, high-sensitivity method validation, or comprehensive nitrosamine risk assessments, access the ResolveMass Laboratories Inc. contact portal directly:
Frequently Asked Questions on Nitrosamine Impurities and Leachables
Nitrosating agents, including nitrites that may originate from manufacturing materials or environmental contamination, can react with secondary amines when conditions such as heat and moisture are present. In elastomeric closures, these secondary amines are often generated from vulcanization accelerators like thiurams and dithiocarbamates used during rubber processing. The interaction between these compounds promotes the formation of volatile nitrosamines. As a result, elastomeric components are considered important sources of potential nitrosamine contamination in pharmaceutical packaging systems.
The sartan recalls were linked to manufacturing process changes that unintentionally created conditions favorable for nitrosamine formation, particularly through the combination of sodium nitrite and amine-containing solvents. This led to the detection of NDMA and NDEA in several products. In contrast, the ranitidine recalls were associated with the inherent instability of the drug molecule itself. Because ranitidine contains both nitro and amine functional groups, it can gradually degrade and generate NDMA during storage, even without exposure to external nitrosating agents.
The FDA recognizes that infusion bags are essential for critical medical applications such as emergency treatments, hospital-based therapies, and parenteral nutrition. To avoid disruptions in the supply of these life-saving products, regulators may permit a temporary adjustment factor of 4- to 10-fold above the standard acceptable intake limit for leachable NDBA. This approach is based on a risk-benefit evaluation that considers the relatively short duration of exposure compared with long-term use of chronic medications. The goal is to maintain patient access to necessary therapies while managing potential risks appropriately.
USP and USP serve different but complementary purposes within extractables and leachables programs. USP focuses on identifying and characterizing extractable compounds that can be released from packaging materials under aggressive laboratory conditions designed to represent worst-case scenarios. USP, on the other hand, addresses the assessment of actual leachables that migrate into a drug product during storage and use. Together, these standards provide a comprehensive framework for evaluating material compatibility and patient safety.
The Carcinogenic Potency Categorization Approach (CPCA) evaluates the structural characteristics of N-nitrosamines to estimate their carcinogenic potential. Factors such as steric hindrance, electronic effects, and metabolic activation pathways are analyzed to assign a compound to one of five potency categories. Each category corresponds to a specific Acceptable Intake (AI) limit, ranging from 18 ng/day for highly potent compounds to 1500 ng/day for substances with significantly lower carcinogenic concern. This science-based framework supports risk assessment when direct toxicological data are unavailable.
The Analytical Evaluation Threshold (AET) is a key tool used to determine which detected compounds require further toxicological assessment during extractables and leachables studies. It is calculated using factors such as the Safety Concern Threshold (SCT) and the product’s maximum daily dose. Compounds detected below the AET are generally considered unlikely to pose a meaningful health risk and may not require extensive investigation. This approach helps laboratories prioritize resources toward substances that could have a greater impact on patient safety.
USP Procedure 3 employs Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) combined with an Atmospheric Pressure Chemical Ionization (APCI) source to achieve highly selective nitrosamine detection. The method uses Multiple Reaction Monitoring (MRM) transitions to track specific precursor and product ion pairs associated with target analytes. This selective monitoring significantly reduces interference from co-eluting compounds present within complex pharmaceutical matrices. As a result, trace nitrosamines can be accurately quantified even in challenging formulations such as sartan drug products.
Analytical methods used for trace-level nitrosamine testing must comply with ICH Q2(R2) validation requirements. Critical performance characteristics include a Limit of Quantitation (LOQ) well below the target specification level, linearity demonstrated by an R² value of at least 0.99, and recovery results typically ranging between 80% and 120%. In addition, the method must demonstrate adequate specificity to ensure that no interfering peaks overlap with the target analyte signals. These validation parameters help ensure accurate, reliable, and reproducible results.
Printed overwrap materials can contribute to nitrosamine formation because certain inks contain dialkylamines, while some formulations utilize nitrocellulose-based binders. During sealing and packaging operations, these materials may be exposed to elevated temperatures and mechanical pressure. Under such conditions, chemical reactions can occur that generate volatile nitrosamines, including NDBA. Once formed, these compounds may migrate through packaging layers and eventually enter the drug product over time.
Reference:
- U.S. Food and Drug Administration. (2025). CDER nitrosamine impurity acceptable intake limits. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cder-nitrosamine-impurity-acceptable-intake-limits
- U.S. Pharmacopeia. (2025, December 17). From nitrosamines to packaging safety: The expanding story of impurities. Quality Matters. https://qualitymatters.usp.org/nitrosamines-packaging-safety-expanding-story-impurities
- U.S. Pharmacopeia. (2025, September 10). Nitrosamines: An urgent demand for vigilance and reliable testing. Quality Matters. https://qualitymatters.usp.org/nitrosamines-an-urgent-demand-for-vigilance-and-reliable-testing
- U.S. Food and Drug Administration. (2024, September). Control of nitrosamine impurities in human drugs: Guidance for industry (Rev. 2). U.S. Department of Health and Human Services. https://www.fda.gov/media/188238/download
- Ogilvie, R. (2019, November 4). ICH M7 principles: Impurity identification and control – Session 3: Prevention Part 1 [Conference presentation]. EMA Sartans with N-nitrosamine Impurities Lessons Learnt Exercise – Interested Parties Meeting, Amsterdam, Netherlands. https://www.ema.europa.eu/en/documents/presentation/presentation-ich-m7-principles-impurity-identification-control-r-ogilvie_en.pdf
- U.S. Food and Drug Administration. (n.d.). Information about nitrosamine impurities in medications. https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications
- Yosukemino. (2024, September 4). EMA Q&A Appendix 1 is updated Sept 4, 2024 [Online forum post]. Nitrosamines Exchange (USP). https://nitrosamines.usp.org/t/ema-q-a-appendix-1-is-updated-sept-4-2024/11202
Get In Touch With Us
About The Author
